Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Cost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsReceivables - NetShares Repurchased
Ratios

BridgeBio Pharma (BBIO) Receivables - Other (2019 - 2024)

BridgeBio Pharma's Receivables - Other history spans 6 years, with the latest figure at $478000.0 for Q3 2024.

  • For Q3 2024, Receivables - Other fell 90.75% year-over-year to $478000.0; the TTM value through Sep 2024 reached $478000.0, down 90.75%, while the annual FY2023 figure was $600000.0, 96.49% down from the prior year.
  • Receivables - Other for Q3 2024 was $478000.0 at BridgeBio Pharma, down from $660000.0 in the prior quarter.
  • Across five years, Receivables - Other topped out at $235.5 million in Q1 2024 and bottomed at $462000.0 in Q1 2021.
  • The 5-year median for Receivables - Other is $8.8 million (2021), against an average of $23.4 million.
  • The largest annual shift saw Receivables - Other skyrocketed 5220.56% in 2022 before it tumbled 96.49% in 2023.
  • A 5-year view of Receivables - Other shows it stood at $8.0 million in 2020, then soared by 146.86% to $19.7 million in 2021, then fell by 13.52% to $17.1 million in 2022, then crashed by 96.49% to $600000.0 in 2023, then decreased by 20.33% to $478000.0 in 2024.
  • Per Business Quant, the three most recent readings for BBIO's Receivables - Other are $478000.0 (Q3 2024), $660000.0 (Q2 2024), and $235.5 million (Q1 2024).